Eric Topol interviews Jennifer Doudna on the bright future of genome editing therapy in curing disease (Apple Podcasts). There’s an FDA-approved CRISPR therapy for sickle cell disease out now with others to come.
Advertise here with Carbon Ads
This site is made possible by member support. ❤️
Big thanks to Arcustech for hosting the site and offering amazing tech support.
When you buy through links on kottke.org, I may earn an affiliate commission. Thanks for supporting the site!
kottke.org. home of fine hypertext products since 1998.
Comments 2
I will read anything and everything about Jennifer Doudna and the work that she does. I'm a complete layman when it comes to microbiology, but dang, the mind *reels* at how much the health and healthspan (vs lifespan) playing field is going to change in the next 20 - 40 years. I'm excited for my 4 year old, and also stressed at the choices she may end up having to make (fix things, don't fix things, etc).
The NPR reporting on the medical trial of the woman with sickle cell who was treated with CRISPR technology is an amazing listen: https://www.npr.org/sections/health-shots/2019/12/25/784395525/a-young-mississippi-womans-journey-through-a-pioneering-gene-editing-experiment
Hello! In order to comment or fave, you need to be a current kottke.org member. If you'd like to sign up for a membership to support the site and join the conversation, you can explore your options here.
Existing members can sign in here. If you're a former member, you can renew your membership.
Note: If you are a member and tried to log in, it didn't work, and now you're stuck in a neverending login loop of death, try disabling any ad blockers or extensions that you have installed on your browser...sometimes they can interfere with the Memberful links. Still having trouble? Email me!
In order to comment or fave, you need to be a current kottke.org member. Check out your options for renewal.
This is the name that'll be displayed next to comments you make on kottke.org; your email will not be displayed publicly. I'd encourage you to use your real name (or at least your first name and last initial) but you can also pick something that you go by when you participate in communities online. Choose something durable and reasonably unique (not "Me" or "anon"). Please don't change this often. No impersonation.
Note: I'm letting folks change their display names because the membership service that kottke.org uses collects full names and I thought some people might not want their names displayed publicly here. If it gets abused, I might disable this feature.
If you feel like this comment goes against the grain of the community guidelines or is otherwise inappropriate, please let me know and I will take a look at it.
Hello! In order to leave a comment, you need to be a current kottke.org member. If you'd like to sign up for a membership to support the site and join the conversation, you can explore your options here.
Existing members can sign in here. If you're a former member, you can renew your membership.
Note: If you are a member and tried to log in, it didn't work, and now you're stuck in a neverending login loop of death, try disabling any ad blockers or extensions that you have installed on your browser...sometimes they can interfere with the Memberful links. Still having trouble? Email me!